Enveric Biosciences (ENVB) Net Cash Flow Growth (5y) (2015 - 2026)
Enveric Biosciences (ENVB) Net Cash Flow Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -58.91% |
| Dec 31, 2025 | -7.72% |
| Sep 30, 2025 | 48.91% |
| Jun 30, 2025 | -24.44% |
| Mar 31, 2025 | 31.74% |
| Dec 31, 2024 | -7.10% |
| Jun 30, 2024 | -87.88% |
| Mar 31, 2024 | 63.10% |
| Dec 31, 2023 | -22.85% |
| Sep 30, 2023 | -34.96% |
| Jun 30, 2023 | -39.30% |
| Mar 31, 2023 | -10.52% |
| Dec 31, 2022 | -23.38% |
| Sep 30, 2022 | 79.28% |
| Jun 30, 2022 | -36.69% |
| Mar 31, 2022 | 58.61% |
| Dec 31, 2021 | -22.65% |
| Sep 30, 2021 | 26.43% |
| Jun 30, 2021 | -21.49% |
| Mar 31, 2021 | 76.91% |